Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Erica A Golemis

Showing results (31-40 of 159) with videos related to

Pageof 16
Sort By:
Methods in Cell Biology|April 6, 2010
Primary cilia and the cell cycleOlga V Plotnikova, Elena N Pugacheva, Erica A Golemis
Biotechniques|April 1, 2003
From correlation to causality: microarrays, cancer, and cancer treatmentGeraldine M O'Neill, Daniel R Catchpoole, Erica A Golemis
European Urology|March 8, 2016
Reply to Francesco Piva, Matteo Santoni, Marina Scarpelli, et al's Letter to the Editor re: Daniel M. Geynisman. Anti-programmed Cell Death Protein 1 (PD-1) Antibody Nivolumab Leads to a Dramatic and Rapid Response in Papillary Renal Cell Carcinoma with Sarcomatoid and Rhabdoid Features. Eur Urol 2015;68:912-4Tim N Beck, Erica A Golemis, Daniel M Geynisman
Cancer Journal (Sudbury, Mass.)|September 27, 2022
Aurora Kinases as Therapeutic Targets in Head and Neck CancerTheodore T Nguyen, Flaviane N Silva, Erica A Golemis
Cancer Research|April 3, 2008
Cell cycle-dependent ciliogenesis and cancerOlga V Plotnikova, Erica A Golemis, Elena N Pugacheva
Plos One|September 3, 2010
Dcas supports cell polarization and cell-cell adhesion complexes in developmentNadezhda Tikhmyanova, Alexei V Tulin, Fabrice Roegiers, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 2, 2017
Musashi RNA-Binding Proteins as Cancer Drivers and Novel Therapeutic TargetsAlexander E Kudinov, John Karanicolas, Erica A Golemis, et al.
Methods in Enzymology|June 8, 2006
Yeast screens for inhibitors of Ras-Raf interaction and characterization of MCP inhibitors of Ras-Raf interactionVladimir Khazak, Juran Kato-Stankiewicz, Fuyu Tamanoi, et al.
Expert Opinion on Therapeutic Targets|November 21, 2007
Selective Raf inhibition in cancer therapyVladimir Khazak, Igor Astsaturov, Ilya G Serebriiskii, et al.
Cancers|September 6, 2019
Tumor-Targeted Drug Conjugates as an Emerging Novel Therapeutic Approach in Small Cell Lung Cancer (SCLC)Alexander Y Deneka, Yanis Boumber, Tim Beck, et al.
Pageof 16

Showing results (31-40 of 159) with videos related to

Sort By:
Pageof 16
Methods in Cell Biology|April 6, 2010
Primary cilia and the cell cycleOlga V Plotnikova, Elena N Pugacheva, Erica A Golemis
Biotechniques|April 1, 2003
From correlation to causality: microarrays, cancer, and cancer treatmentGeraldine M O'Neill, Daniel R Catchpoole, Erica A Golemis
European Urology|March 8, 2016
Reply to Francesco Piva, Matteo Santoni, Marina Scarpelli, et al's Letter to the Editor re: Daniel M. Geynisman. Anti-programmed Cell Death Protein 1 (PD-1) Antibody Nivolumab Leads to a Dramatic and Rapid Response in Papillary Renal Cell Carcinoma with Sarcomatoid and Rhabdoid Features. Eur Urol 2015;68:912-4Tim N Beck, Erica A Golemis, Daniel M Geynisman
Cancer Journal (Sudbury, Mass.)|September 27, 2022
Aurora Kinases as Therapeutic Targets in Head and Neck CancerTheodore T Nguyen, Flaviane N Silva, Erica A Golemis
Cancer Research|April 3, 2008
Cell cycle-dependent ciliogenesis and cancerOlga V Plotnikova, Erica A Golemis, Elena N Pugacheva
Plos One|September 3, 2010
Dcas supports cell polarization and cell-cell adhesion complexes in developmentNadezhda Tikhmyanova, Alexei V Tulin, Fabrice Roegiers, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 2, 2017
Musashi RNA-Binding Proteins as Cancer Drivers and Novel Therapeutic TargetsAlexander E Kudinov, John Karanicolas, Erica A Golemis, et al.
Methods in Enzymology|June 8, 2006
Yeast screens for inhibitors of Ras-Raf interaction and characterization of MCP inhibitors of Ras-Raf interactionVladimir Khazak, Juran Kato-Stankiewicz, Fuyu Tamanoi, et al.
Expert Opinion on Therapeutic Targets|November 21, 2007
Selective Raf inhibition in cancer therapyVladimir Khazak, Igor Astsaturov, Ilya G Serebriiskii, et al.
Cancers|September 6, 2019
Tumor-Targeted Drug Conjugates as an Emerging Novel Therapeutic Approach in Small Cell Lung Cancer (SCLC)Alexander Y Deneka, Yanis Boumber, Tim Beck, et al.
Pageof 16